Bath & Body Works Inc. (0JSC)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 21.72 |
|---|---|
| 52-week range | 14.37 – 27.20 |
| Return, 1 month / 3 months | +31.5% / +6.1% |
| Return, 1 year / 3 years | −15.9% / −20.4% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 61.2% |
| Worst drawdown (1 year) | -37.3% |
| Average daily value traded | 0.10M USD |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bath & Body Works is an American retailer focused on personal care and home fragrance. It sells body lotions, shower gels, hand soaps, sanitizers, and scented candles, along with related accessories, mainly through its own shops and online store. Its customers are everyday shoppers looking for affordable scented products and gifts, and the company is based in the United States, where most of its stores are located.
Bath & Body Works Inc. trades under the code 0JSC on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bath & Body Works Inc. (0JSC) trades on the London Stock Exchange in UK. It last closed at USD 21.72 on 27 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 2,649 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 15.9% and over the last three months it rose 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.6% | ||
| From 52-week high | -16.8% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.1% | ||
| 6-month return | 13.4% | ||
| 12-month return, skipping the last month | -36.1% | ||
| Stability (higher is calmer) | 27 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 61.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.3% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 28 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.9% |
|---|---|
| 1 month | +31.5% |
| 3 months | +6.1% |
| 6 months | +13.4% |
| 1 year | −15.9% |
| 3 years | −20.4% |
| 5 years | −65.5% |
Signals
| 50-day / 200-day average | 18.42 / 19.82 |
|---|---|
| Golden / death cross (60 days) | Death, 36 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.84 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Nov 2025 | USD 0.2000 |
| 22 Aug 2025 | USD 0.2000 |
| 5 Jun 2025 | USD 0.2000 |
| 21 Feb 2025 | USD 0.2000 |
| 22 Nov 2024 | USD 0.2000 |
| 23 Aug 2024 | USD 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.